MPM BioImpact
MPM BioImpact is a biotechnology investment firm that builds and funds companies across the drug development process to transform scientific breakthroughs into medicines. The firm combines 30+ years of MPM CAPITAL biotech investing with BioImpact’s public-investing experience, manages over $3 billion AUM across early-stage venture funds, private/public impact funds and a public equities fund, and reports outcomes including 60 FDA‑approved drugs and 120+ M&A and IPO events. MPM BioImpact uses Entrepreneur Partners and an active company-creation model to provide domain expertise, operational capabilities and strategic support to portfolio companies.
Industries
Nr. of Employees
small (1-50)
MPM BioImpact
399 Boylston Street, Suite 1100, Boston, MA 02116
Portfolio
Develops circular RNA (oRNA) and non-viral delivery; collaboration with Vertex Pharmaceuticals on sickle cell disease and transfusion-dependent beta thalassemia noted in news.
#RNA therapeutics (circular RNA)
Developing miniprotein actinium-conjugates (targeted alpha radiopharmaceuticals); raised significant financings (e.g., oversubscribed $175M Series B referenced).
#Radiopharmaceuticals / oncology
Combines manufacturing, next-generation technologies, and therapeutic development under one roof; referenced in collaborations and press.
#Cell, gene, and RNA therapy manufacturing and technologies
Translating a research breakthrough targeting HHLA2 into precision cancer therapies.
#Oncology (novel immunotherapies)
#Cell therapy / oncology
Closed a $53M Series E equity financing (April 27, 2023) per site news.
#Biotech / therapeutics
Develops circular RNA (oRNA) and non-viral delivery; collaboration with Vertex Pharmaceuticals on sickle cell disease and transfusion-dependent beta thalassemia noted in news.
#RNA therapeutics (circular RNA)
Developing miniprotein actinium-conjugates (targeted alpha radiopharmaceuticals); raised significant financings (e.g., oversubscribed $175M Series B referenced).
#Radiopharmaceuticals / oncology
Combines manufacturing, next-generation technologies, and therapeutic development under one roof; referenced in collaborations and press.
#Cell, gene, and RNA therapy manufacturing and technologies
Translating a research breakthrough targeting HHLA2 into precision cancer therapies.
#Oncology (novel immunotherapies)
#Cell therapy / oncology
Closed a $53M Series E equity financing (April 27, 2023) per site news.
#Biotech / therapeutics